hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.20471/LO.2018.46.01.04

Driver mutations in melanoma

Snježana Ramić   ORCID icon orcid.org/0000-0002-5916-8815 ; Department of Oncological Pathology, ‘Ljudevit Jurak’ University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Melita Perić Balja ; Department of Oncological Pathology, ‘Ljudevit Jurak’ University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia

Puni tekst: engleski, pdf (214 KB) str. 24-28 preuzimanja: 226* citiraj
APA 6th Edition
Ramić, S. i Perić Balja, M. (2018). Driver mutations in melanoma. Libri Oncologici, 46 (1), 24-28. https://doi.org/10.20471/LO.2018.46.01.04
MLA 8th Edition
Ramić, Snježana i Melita Perić Balja. "Driver mutations in melanoma." Libri Oncologici, vol. 46, br. 1, 2018, str. 24-28. https://doi.org/10.20471/LO.2018.46.01.04. Citirano 27.10.2021.
Chicago 17th Edition
Ramić, Snježana i Melita Perić Balja. "Driver mutations in melanoma." Libri Oncologici 46, br. 1 (2018): 24-28. https://doi.org/10.20471/LO.2018.46.01.04
Harvard
Ramić, S., i Perić Balja, M. (2018). 'Driver mutations in melanoma', Libri Oncologici, 46(1), str. 24-28. https://doi.org/10.20471/LO.2018.46.01.04
Vancouver
Ramić S, Perić Balja M. Driver mutations in melanoma. Libri Oncologici [Internet]. 2018 [pristupljeno 27.10.2021.];46(1):24-28. https://doi.org/10.20471/LO.2018.46.01.04
IEEE
S. Ramić i M. Perić Balja, "Driver mutations in melanoma", Libri Oncologici, vol.46, br. 1, str. 24-28, 2018. [Online]. https://doi.org/10.20471/LO.2018.46.01.04

Sažetak
In this review, we present the findings from the literature on several new molecules that can be targeted in the melanoma treatment process, especially metastatic melanoma, since five-year survival rates are below 20%. Recently, melanoma has been defined by mutations that occur in oncogenes and lead to melanomagenesis. A mutation in BRAF gene selects the patients for targeting therapy with BRAF inhibitors. Although BRAF inhibitor therapy is associated with clinical benefit, the majority of patients with the BRAFV600-mutated metastatic melanoma develop resistance, usually within the first year. Clinically significant discrepancy in BRAF status, between primary melanoma and its metastasis were detected in about 15% of cases. There are no specific recommendations on BRAF re-testing, but might be clinically relevant to repeat testing on recent metastatic sites in cases of previous BRAF wild type results.

Ključne riječi
metastatic melanoma; BRAF; p53; signaling pathway; mutations

Hrčak ID: 204693

URI
https://hrcak.srce.hr/204693

[hrvatski]

Posjeta: 518 *